Small Interfering RNA (siRNA) News and Research

RSS

RXi Pharmaceuticals announces financial results for the quarter ended September 30, 2009

16 Nov 2009

RXi receives USPTO notices of allowance for certain siRNA sequence-specific patent applications

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that Notices of Allowance were recently issued by the United States Patent Office (USPTO) on patent applications filed by Thermo Fisher Scientific Inc. and licensed to RXi Pharmaceuticals encompassing small interfering RNA (siRNA) sequences targeting superoxide dismutase (SOD1), Amyloid beta (A4) precursor protein (APP), interleukin-1 receptor-associated kinase 4 (IRAK4), hepatocyte growth factor receptor (MET protooncogene) and cyclin-dependent kinase (cdk) inhibitor p27 (also known as Kip1, CDKN1B).

From Thermo Fisher Scientific Inc. 3 Oct 2009

Alnylam and Medtronic announce pre-clinical research findings from their Huntington’s disease program

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Medtronic, Inc. (NYSE: MDT), the world’s leading developer of medical devices, announced today the presentation of new pre-clinical research findings from their Huntington’s disease program at the 2009 World Congress on Huntington’s Disease held September 12-15, 2009 in Vancouver, British Columbia.

15 Sep 2009

USPTO allows Isis an additional patent for single-stranded RNAi technology

Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today that the United States Patent and Trademark Office (USPTO) has allowed an Isis patent application that further expands the scope of the "Crooke" patent estate. The newly allowed patent broadly covers methods of cleaving a target RNA via a double-stranded ribonuclease mechanism, including the RNAi mechanism, with chemically modified, single-stranded RNA-containing drugs.

11 Sep 2009

Iowa researchers modify siRNA for impacting targeted cells in cancer treatment

Small interfering RNA (siRNA), a type of genetic material, can block potentially harmful activity in cells, such as tumor cell growth. But delivering siRNA successfully to specific cells without adversely affecting other cells has been challenging.

28 Aug 2009

Nanoparticle Trojan horse for ovarian cancer

In a feat of trickery, Dartmouth Medical School immunologists have devised a Trojan horse to help overcome ovarian cancer, unleashing a surprise killer in the surroundings of a hard-to-treat tumor.

19 Jul 2009

Scientists block Ebola infection in cell-culture experiments - could lead to first therapy

Researchers at the University of Texas Medical Branch at Galveston have discovered two biochemical pathways that the Ebola virus relies on to infect cells.

23 Jun 2009

New kind of treatment for sexually transmitted diseases

Yale researchers describe a breakthrough in safe and effective administration of potential antiviral drugs - small interfering RNA (siRNA) molecules that silence genes - the first step in development of a new kind of treatment for sexually transmitted diseases (STDs). The work is reported May 4 as an advance online publication of Nature Materials.

3 May 2009

Oral delivery system for RNAi therapeutics

Researchers at the University of Massachusetts Medical School (UMMS) report on a novel approach to the delivery of small bits of genetic material in order to silence genes using "RNA interference"-and in the process, discovered a potent method of suppressing inflammation in mice similar to what occurs in a range of human diseases.

30 Apr 2009

Intradigm receives notice of allowance for key RNA interference patent covering potent siRNA sequence

Intradigm Corporation, a leading developer of targeted, systemic RNA interference (RNAi) therapeutics, has announced that the United States Patent and Trademark Office (USPTO) has issued the company a notice of allowance for a patent covering various aspects of a potent small interfering RNA (siRNA) sequence.

17 Mar 2009

Gold nanoparticles improve gene regulation

Investigators at Northwestern University have found that packing small interfering RNA (siRNA) molecules onto the surface of a gold nanoparticle can protect siRNAs from degradation and increase their ability to regulate genes involved in cancer. As a result of this discovery, cancer researchers have at their disposal a relatively straightforward method of delivering these potent gene-regulating agents into targeted cells.

23 Feb 2009

New inhibitors could be new class of cancer drugs

A team of Vanderbilt University Medical Center investigators has developed a group of chemical compounds that could represent a new class of drugs for treating cancer.

3 Feb 2009

Microfluidic devices capture and analyze single cancer cells

One of the grand goals in nanotechnology is to develop a single microfluidic device that integrates all of the components needed to perform polymerase chain reaction (PCR)-based nucleic acid analyses. Experts predict that such a device would enable researchers to develop rapid assays for cancer and other life-threatening diseases while a patient is in the doctor's office.

18 Jan 2009

Researchers stop ovarian cancer cell cycle in its tracks

Ovarian cancer cells are "addicted" to a family of proteins produced by the notorious oncogene, MYC, and blocking these Myc proteins halts cell proliferation in the deadliest cancer of the female reproductive system, according to a presentation by University of California, Berkeley scientists at the American Society for Cell Biology (ASCB) 48th Annual Meeting, Dec. 13-17, 2008 in San Francisco.

15 Dec 2008

Blocking Myc proteins stops ovarian cancer cell cycle in its tracks

Ovarian cancer cells are "addicted" to a family of proteins produced by the notorious oncogene, MYC.

15 Dec 2008

RNA interference can facilitate vaccine development

Pharmaceutical companies and universities are racing to develop drugs that use the gene silencing mechanism known as RNA interference to treat a host of diseases.

10 Dec 2008

Researchers map changing epigenetic modifications that enable transposons to run amok

Cold Spring Harbor, N.Y. – Much like cancer cells, plant cells grown for a long time outside of their normal milieu, in culture dishes, have highly unstable genomes.

10 Dec 2008

Nanoparticle targets melanoma with siRNA

Research has shown that a particular receptor for the blood protein thrombin is overexpressed by highly metastatic melanoma cells.

20 Nov 2008

Nanoparticles target multiple cancer genes, shrink tumors more effectively

Nanoparticles filled with small interfering RNA (siRNA) molecules targeting two genes that trigger melanoma have shown that they can inhibit the development of melanoma, the most dangerous type of skin cancer.

27 Oct 2008

Designer RNA fights high cholesterol, medical researchers find

Small, specially designed bits of ribonucleic acid (RNA) can interfere with cholesterol metabolism, reducing harmful cholesterol by two-thirds in pre-clinical tests, according to a new study by researchers at UT Southwestern Medical Center in collaboration with Alnylam Pharmaceuticals and the Massachusetts Institute of Technology.

11 Aug 2008